NCT07281001

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Blokhin's Russian Cancer Research Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Detailed description

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation The aim of this trial is to explore the real-world effectiveness T-Dxd and potential predictors in Russian metastatic breast cancer patients

Conditions

• HER2-positive Breast Cancer
• Trastuzumab Deruxtecan

Interventions

Type	Name	Description
DRUG	T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.	T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2025-12-15
• Last updated: 2025-12-15

Locations

1 site across 1 country: Russia